Identifying the clinical domains of fibromyalgia: Contributions from clinician and patient delphi exercises
dc.contributor.author | Mease, Philip J. | en_US |
dc.contributor.author | Arnold, Lesley M. | en_US |
dc.contributor.author | Crofford, Leslie J. | en_US |
dc.contributor.author | Williams, David A. | en_US |
dc.contributor.author | Russell, I. Jon | en_US |
dc.contributor.author | Humphrey, Louise | en_US |
dc.contributor.author | Abetz, Linda | en_US |
dc.contributor.author | Martin, Susan A. | en_US |
dc.date.accessioned | 2008-08-04T15:13:38Z | |
dc.date.available | 2009-08-12T18:32:18Z | en_US |
dc.date.issued | 2008-07-15 | en_US |
dc.identifier.citation | Mease, Phillip J.; Arnold, Lesley M.; Crofford, Leslie J.; Williams, David A.; Russell, I. Jon; Humphrey, Louise; Abetz, Linda; Martin, Susan A. (2008). "Identifying the clinical domains of fibromyalgia: Contributions from clinician and patient delphi exercises." Arthritis & Rheumatism 59(7): 952-960. <http://hdl.handle.net/2027.42/60452> | en_US |
dc.identifier.issn | 0004-3591 | en_US |
dc.identifier.issn | 1529-0131 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/60452 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=18576290&dopt=citation | en_US |
dc.description.abstract | Objective In evaluating the effectiveness of fibromyalgia (FM) therapies, it is important to assess the impact of those therapies on the full array of domains considered important by both clinicians and patients. The objective of this research was to identify and prioritize the key clinically relevant and important domains impacted by FM that should be evaluated by outcome assessment instruments used in FM clinical trials, and to approach consensus among clinicians and patients on the priority of those domains to be assessed in clinical care and research. Methods Group consensus was achieved using the Delphi method, a structured process of consensus building via questionnaires together with systematic and controlled opinion feedback. The Delphi exercises involved 23 clinicians with expertise in FM and 100 patients with FM as defined by American College of Rheumatology criteria. Results The Delphi exercise revealed that the domains ranked most highly by patients were similar to the domain rankings by clinicians. Pain was consistently ranked highest by both panels. Fatigue, impact on sleep, health-related quality of life, comorbid depression, and cognitive difficulty were also ranked highly. Stiffness was ranked highly by patients but not clinicians. In contrast, side effects was important to clinicians but was not identified as important in the patient Delphi exercise. Conclusion The clinician and patient Delphi exercises identified and ranked key domains that need to be assessed in FM research. Based on these results, a conceptual framework for measuring patient-reported outcomes is proposed. | en_US |
dc.format.extent | 111577 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.title | Identifying the clinical domains of fibromyalgia: Contributions from clinician and patient delphi exercises | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Geriatrics | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | University of Michigan, Ann Arbor ; Dr. Williams has received consultant fees (less than $10,000 each) from Eli Lilly, Cypress Biosciences, Forest, and Pierre Fabre. | en_US |
dc.contributor.affiliationother | Seattle Rheumatology Associates, Seattle, Washington ; Dr. Mease has received consultant fees and grant/research support (less than $10,000 each) from Pfizer, Cypress Biosciences, Forest, Eli Lilly, Allergan, Fralex, Boehringer-Ingelheim, Jazz, Wyeth, and Pierre Fabre, and has received speaking fees (less than $10,000) from Pfizer. ; Seattle Rheumatology Associates, 1101 Madison Street, Suite 1000, Seattle, WA 98104 | en_US |
dc.contributor.affiliationother | University of Cincinnati, Cincinnati, Ohio ; Dr. Arnold has received consultant fees, speaking fees, and/or grant/research support (less than $10,000 each) from Cypress Bio sciences, Boehringer-Ingelheim, Forest, Allergan, Organon, Sanofi-Aventis, Sepracor, and Vivus, and (more than $10,000 each) from Eli Lilly, Pfizer, and Wyeth. | en_US |
dc.contributor.affiliationother | University of Kentucky, Lexington ; Dr. Crofford has received consultant fees and/or grant/research support (less than $10,000 each) from Pfizer, Eli Lilly, Allergan, and Wyeth. | en_US |
dc.contributor.affiliationother | University of Texas, San Antonio ; Dr. Russell has received consultant fees, speaking fees, and/or honoraria (less than $10,000) from Lilly and (more than $10,000 each) from Pfizer and Jazz. | en_US |
dc.contributor.affiliationother | Mapi Values, Bollington, UK ; Ms Humphrey and Ms Abetz received research/grant support from Pfizer and were contracted by Pfizer to assist in the present study. | en_US |
dc.contributor.affiliationother | Mapi Values, Bollington, UK | en_US |
dc.contributor.affiliationother | Pfizer, Ann Arbor, Michigan ; Ms Martin owns stock in Pfizer. | en_US |
dc.identifier.pmid | 18576290 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/60452/1/23826_ftp.pdf | |
dc.identifier.doi | http://dx.doi.org/10.1002/art.23826 | en_US |
dc.identifier.source | Arthritis & Rheumatism | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.